13
Views
27
CrossRef citations to date
0
Altmetric
Original Article

Comparative findings on serum IMg2+ of normal and diseased human subjects with the Nova and Kone Ise's for Mg2+

, , , &
Pages 77-81 | Published online: 08 Jul 2009
 

Abstract

Altura BT, Bertschat, F, Jeremias, A, Ising H, Altura BM. Comparative findings on serum IMg2+ of normal and diseased human subjects with the NOVA and KONE ISE's for Mg2+. Scand J Clin Lab Invest 1994; 54, Suppl 217: 77-81.

It is clear now that although different ionophores for ionized Mg (IMg2+) have been designed by several groups, each of these has a distinctly different KMgCa. In view of this, it is important to determine whether each of these ion selective electrodes (ISE's) yield identical results for IMg2+ in sera from healthy and diseased humans. Using such an approach, we determined, in a blinded-and random manner, IMg with both the NOVA and KONE ISE's for IMg2+ in two independent laboratories. No significant differences were found either for sera from healthy human volunteers or diseased patients. We did, however, note several interesting findings: 1. randomly, selected hospitalized patients exhibit a much higher incidence of abnormalities for IMg2+ (57–71%) than that noted previously for total Mg (TMg) measurements; and 2. coronary heart disease, rectal cancer and multiple sclerosis patients exhibit extracellular deficits in ionized free Mg.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.